Corporate News

You are here:

Home
Corporate News

Advance AI-Driven Human Tissue Research Using StemRNA™ iPSCs

REPROCELL and Polyphron Announce Collaboration to Advance AI-Driven Human Tissue Research Using StemRNA™ iPSCs

REPROCELL Expands Clinical iPSC and Stem Cell Solutions in China Through Strategic Collaboration with WEIPU Biotechnology

REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)

Bioserve – A REPROCELL Company Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

Bioserve – A REPROCELL COMPANY Launches StemEdit: Clinical Gene Editing Services and New iPSC Lines Using AI-Designed Editing System

REPROCELL and Histocell have achieved GMP certification for their manufacturing process of clinical-grade iPSC master and working cell banks using StemRNA™ Clinical iPSCs, ensuring high-quality and safe production for regenerative medicine applications.

REPROCELL Unveils Cutting-Edge Neoantigen Detection Service to Propel Precision Cancer Immunotherapy

REPROCELL and Durham University Researchers Develop iPSC-Derived Full-Thickness Human Skin Model

Exclusive Distribution Agreement with HLB PEP in India

Notice Regarding Announcement by Partner Steminent Biotherapeutics Inc. of Phase II Clinical Trial Results in Taiwan for Spinocerebellar Ataxia Treatment “Stemchymal®”

World’s First Live Birth Using REPROCELL’s StemRNA Clinical Seed iPSCs for Oocyte Maturation Outside of the Body

World’s First Live Birth Using REPROCELL’s StemRNA Clinical Seed iPSCs for Oocyte Maturation Outside of the Body

Qkine announces partnership with REPROCELL

Bioserve India Launches Advanced Stem Cell Products in India

REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells

Bioserve Biotechnologies and RISVI Trading Announce New Distributorship Agreement in Qatar

Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market.

REPROCELL invests in Histocell, S.L. a Spain-based CDMO